You can buy or sell Synlogic and other stocks, options, ETFs, and crypto commission-free!
Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. Read More It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2018 Results - Earnings Call Transcript
Synlogic, Inc. (NASDAQ:SYBX) Q4 2016 Results Earnings Conference Call March 12, 2019 8:00 AM ET Company Participants Elizabeth Wolffe - Head, Investor Relations and Corporate Communications Aoife Brennan - President, Chief Executive Officer and Chief Medical Officer Todd Shegog - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Mark Breidenbach - Oppenheimer & Co Inc. Ted Tenthoff - Piper Jaffray & Co. Raghuram Selvaraju - H.C. Wainwright & Co. Joseph Schwartz - S...
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2018. “2019 is an exciting year for Synlogic as we continue to advance out platform and programs,” said Aoife Brennan, M.B., Ch.B. Synlogic’s president and chief executive officer. “Data expected mid-year from clinical trials of SYNB1020 and SYNB1618...
Seeking AlphaMar 6
Synlogic progressing IBD partnership with AbbVie
Synlogic (NASDAQ:SYBX) has advanced its Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie (NYSE:ABBV) to develop an oral treatment for inflammatory bowel disease (IBD). The companies have been working together on the project since February 2016....
-$0.54 per share
-$0.47 per share